导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.01% | 1968/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.42% | 2458/5421 |
| 近一季 | -6.34% | 2053/5209 |
| 近半年 | 1.01% | 1092/4920 |
| 近一年 | 3.33% | 1947/4366 |
| 近两年 | 51.22% | 1435/2954 |
| 近三年 | 34.72% | 879/2253 |
| 成立以来 | 70.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.51% 3640/4961 |
16.66% 1539/5312 |
- - |
- - |
| 2025 | 20.73% 2097/4813 |
0.25% 1933/3635 |
2.77% 1370/4076 |
17.41% 2509/4524 |
-0.18% 2404/4813 |
| 2024 | 18.57% 591/3463 |
2.92% 666/2808 |
-0.36% 747/3014 |
15.53% 1692/3129 |
0.07% 1273/3463 |
| 2023 | -9.00% 1087/2656 |
3.15% 1252/2280 |
-3.57% 833/2385 |
-2.31% 662/2515 |
-6.35% 1734/2655 |
| 2022 | -17.92% 641/2207 |
-11.99% 560/1919 |
5.34% 917/2016 |
-12.77% 778/2113 |
1.48% 1250/2208 |
| 2021 | 5.34% 548/1822 |
0.32% 302/1255 |
6.66% 731/1330 |
-4.21% 692/1466 |
2.77% 523/1822 |
| 2020 | 39.74% 325/1250 |
-8.96% 642/1028 |
13.60% 605/1067 |
18.61% 78/1164 |
13.92% 323/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.54% 306/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 银河沪深300指数增强C VS. 长安沪深300非周期A(740101) |